Liang JIANG ; Yuting WANG ; Qian LI ; Zhengchao TU ; Sihua ZHU ; Sanfang TU ; Zhang ZHANG ; Ke DING ; Xiaoyun LU
Acta Pharmaceutica Sinica B 2021;11(5):1315-1328
Bcr-Abl threonine 315 to isoleucine 315 (T315I) gatekeeper mutation induced drug resistance remains an unmet clinical challenge for the treatment of chronic myeloid leukemia (CML). Chemical degradation of Bcr-Abl